{"id":55242,"date":"2026-01-23T06:37:09","date_gmt":"2026-01-22T22:37:09","guid":{"rendered":"https:\/\/flcube.com\/?p=55242"},"modified":"2026-01-23T06:37:10","modified_gmt":"2026-01-22T22:37:10","slug":"primegenx-therapeutics-files-for-hong-kong-ipo-with-jak-stat-pipeline","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=55242","title":{"rendered":"PrimeGenX Therapeutics Files for Hong Kong IPO with JAK\u2011STAT Pipeline"},"content":{"rendered":"\n<p><strong>PrimeGenX Therapeutics Co., Ltd.<\/strong>, a Beijing\u2011based immune\u2011inflammatory disease specialist founded in 2016, has filed for a listing on the <strong>Hong Kong Stock Exchange<\/strong>. The company is developing a pipeline of <strong>first\u2011in\u2011class therapies<\/strong> targeting the synergistic effects of <strong>JAK\u2011STAT pathway signaling and immune cell activation regulation<\/strong> to address chronic diseases with significant unmet medical needs.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-company-profile-amp-ipo-filing\">Company Profile &amp; IPO Filing<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>PrimeGenX Therapeutics Co., Ltd.<\/td><\/tr><tr><td><strong>Founded<\/strong><\/td><td>2016<\/td><\/tr><tr><td><strong>Focus<\/strong><\/td><td>Immune\u2011inflammatory disease specialist<\/td><\/tr><tr><td><strong>Technology Platform<\/strong><\/td><td>JAK\u2011STAT pathway + immune cell activation regulation<\/td><\/tr><tr><td><strong>Filing<\/strong><\/td><td>Hong Kong Stock Exchange listing application<\/td><\/tr><tr><td><strong>Pipeline Stage<\/strong><\/td><td>Preclinical to early clinical<\/td><\/tr><tr><td><strong>Key Innovation<\/strong><\/td><td>Original molecular designs targeting extracellular immune signal transmission<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-pipeline-overview\">Pipeline Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Product<\/th><th>Formulation<\/th><th>Indication<\/th><th>Status<\/th><\/tr><\/thead><tbody><tr><td><strong>PG\u2011011<\/strong><\/td><td>Pumecitinib gel &amp; nasal spray<\/td><td>Inflammatory dermatologic &amp; respiratory conditions<\/td><td>Preclinical<\/td><\/tr><tr><td><strong>PG\u2011033<\/strong><\/td><td>Small molecule \/ biologic<\/td><td>Pruritus (chronic itch)<\/td><td>Preclinical<\/td><\/tr><tr><td><strong>PG\u2011018<\/strong><\/td><td>Small molecule \/ biologic<\/td><td>Autoimmune kidney diseases<\/td><td>Discovery<\/td><\/tr><tr><td><strong>PG\u2011040<\/strong><\/td><td>Eye drops<\/td><td>Glaucoma<\/td><td>Preclinical<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Pipeline Strategy:<\/strong> All candidates leverage <strong>first\u2011in\u2011class potential<\/strong> via novel JAK\u2011STAT modulation and immune cell activation control.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity-amp-strategic-positioning\">Market Opportunity &amp; Strategic Positioning<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>China Immune\u2011Inflammatory Market:<\/strong> Market valued at <strong>\u00a580\u202fbillion<\/strong> (~US$11\u202fbillion) in 2025, growing at <strong>12% CAGR<\/strong> driven by rising chronic disease prevalence<\/li>\n\n\n\n<li><strong>IPO Market Context:<\/strong> Hong Kong biotech listings rebounded in 2025, with investors seeking platforms with differentiated science and clear first\u2011in\u2011class potential<\/li>\n\n\n\n<li><strong>Competitive Moat:<\/strong> PrimeGenX\u2019s dual\u2011target approach (JAK\u2011STAT + immune cell activation) may offer superior efficacy versus single\u2011pathway inhibitors<\/li>\n\n\n\n<li><strong>Valuation Expectations:<\/strong> Analysts estimate <strong>US$300\u2013500\u202fmillion<\/strong> pre\u2011money valuation based on pipeline novelty and platform scalability<\/li>\n\n\n\n<li><strong>Use of Proceeds:<\/strong> Filing indicates funds will advance PG\u2011011 into IND\u2011enabling studies and expand discovery platform<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding PrimeGenX\u2019s IPO timeline, pipeline development, and market potential. Actual results may differ due to regulatory review outcomes, clinical trial risks, and market conditions affecting biotech listings.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/sehk26012101035_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of sehk26012101035_c.\"><\/object><a id=\"wp-block-file--media-9f435f10-e858-4ce6-8746-b6247c4a8c56\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/sehk26012101035_c.pdf\">sehk26012101035_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/sehk26012101035_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-9f435f10-e858-4ce6-8746-b6247c4a8c56\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>PrimeGenX Therapeutics Co., Ltd., a Beijing\u2011based immune\u2011inflammatory disease specialist founded in 2016, has filed for&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[72],"class_list":["post-55242","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-ipo"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>PrimeGenX Therapeutics Files for Hong Kong IPO with JAK\u2011STAT Pipeline - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"PrimeGenX Therapeutics Co., Ltd., a Beijing\u2011based immune\u2011inflammatory disease specialist founded in 2016, has filed for a listing on the Hong Kong Stock Exchange. The company is developing a pipeline of first\u2011in\u2011class therapies targeting the synergistic effects of JAK\u2011STAT pathway signaling and immune cell activation regulation to address chronic diseases with significant unmet medical needs.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=55242\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"PrimeGenX Therapeutics Files for Hong Kong IPO with JAK\u2011STAT Pipeline\" \/>\n<meta property=\"og:description\" content=\"PrimeGenX Therapeutics Co., Ltd., a Beijing\u2011based immune\u2011inflammatory disease specialist founded in 2016, has filed for a listing on the Hong Kong Stock Exchange. The company is developing a pipeline of first\u2011in\u2011class therapies targeting the synergistic effects of JAK\u2011STAT pathway signaling and immune cell activation regulation to address chronic diseases with significant unmet medical needs.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=55242\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-22T22:37:09+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-22T22:37:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55242#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55242\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"PrimeGenX Therapeutics Files for Hong Kong IPO with JAK\u2011STAT Pipeline\",\"datePublished\":\"2026-01-22T22:37:09+00:00\",\"dateModified\":\"2026-01-22T22:37:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55242\"},\"wordCount\":321,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"IPO\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=55242#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55242\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=55242\",\"name\":\"PrimeGenX Therapeutics Files for Hong Kong IPO with JAK\u2011STAT Pipeline - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-01-22T22:37:09+00:00\",\"dateModified\":\"2026-01-22T22:37:10+00:00\",\"description\":\"PrimeGenX Therapeutics Co., Ltd., a Beijing\u2011based immune\u2011inflammatory disease specialist founded in 2016, has filed for a listing on the Hong Kong Stock Exchange. The company is developing a pipeline of first\u2011in\u2011class therapies targeting the synergistic effects of JAK\u2011STAT pathway signaling and immune cell activation regulation to address chronic diseases with significant unmet medical needs.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55242#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=55242\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55242#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"PrimeGenX Therapeutics Files for Hong Kong IPO with JAK\u2011STAT Pipeline\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"PrimeGenX Therapeutics Files for Hong Kong IPO with JAK\u2011STAT Pipeline - Insight, China&#039;s Pharmaceutical Industry","description":"PrimeGenX Therapeutics Co., Ltd., a Beijing\u2011based immune\u2011inflammatory disease specialist founded in 2016, has filed for a listing on the Hong Kong Stock Exchange. The company is developing a pipeline of first\u2011in\u2011class therapies targeting the synergistic effects of JAK\u2011STAT pathway signaling and immune cell activation regulation to address chronic diseases with significant unmet medical needs.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=55242","og_locale":"en_US","og_type":"article","og_title":"PrimeGenX Therapeutics Files for Hong Kong IPO with JAK\u2011STAT Pipeline","og_description":"PrimeGenX Therapeutics Co., Ltd., a Beijing\u2011based immune\u2011inflammatory disease specialist founded in 2016, has filed for a listing on the Hong Kong Stock Exchange. The company is developing a pipeline of first\u2011in\u2011class therapies targeting the synergistic effects of JAK\u2011STAT pathway signaling and immune cell activation regulation to address chronic diseases with significant unmet medical needs.","og_url":"https:\/\/flcube.com\/?p=55242","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-22T22:37:09+00:00","article_modified_time":"2026-01-22T22:37:10+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=55242#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=55242"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"PrimeGenX Therapeutics Files for Hong Kong IPO with JAK\u2011STAT Pipeline","datePublished":"2026-01-22T22:37:09+00:00","dateModified":"2026-01-22T22:37:10+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=55242"},"wordCount":321,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["IPO"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=55242#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=55242","url":"https:\/\/flcube.com\/?p=55242","name":"PrimeGenX Therapeutics Files for Hong Kong IPO with JAK\u2011STAT Pipeline - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-01-22T22:37:09+00:00","dateModified":"2026-01-22T22:37:10+00:00","description":"PrimeGenX Therapeutics Co., Ltd., a Beijing\u2011based immune\u2011inflammatory disease specialist founded in 2016, has filed for a listing on the Hong Kong Stock Exchange. The company is developing a pipeline of first\u2011in\u2011class therapies targeting the synergistic effects of JAK\u2011STAT pathway signaling and immune cell activation regulation to address chronic diseases with significant unmet medical needs.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=55242#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=55242"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=55242#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"PrimeGenX Therapeutics Files for Hong Kong IPO with JAK\u2011STAT Pipeline"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55242","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=55242"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55242\/revisions"}],"predecessor-version":[{"id":55245,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55242\/revisions\/55245"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=55242"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=55242"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=55242"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}